《新股消息》康德莱医疗器械(01501.HK):国家政策利好市场发展
康德莱医疗器械(01501.HK)今日(28日)起招股,董事会主席兼总经理梁栋科表示,日本及欧美等发达国家的经皮冠状动脉介入治疗(PCI)手术使用率是中国的数倍,加上中国近年对医疗器械行业推出不少支持政策,相信未来仍有很大发展空间,今年PCI器械市场规模或达60亿元人民币。
目前该公司旗下有16款在研产品,预计最快於明年首季至2022年面市。他透露,计划在未来五年运用集资所得约19.6%,用作3至5项战略收购或投资,目标优先关注日本、以色列、美国等技术先进地区的早期产品或技术,预计每项投资不超过1,000万美元。
保荐人代表、交银国际企业融资及环球资本市场部董事总经理陈永泰指,康德莱医疗器械认购反应不俗,目前国际配售部份已超购逾三倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.